manzamine a profile

manzamine A: RN given refers to (1R-(1R*,9Z,13S*,13aR*,20aR*,21aR*)-isomer; RN for cpd without isomeric designation not avail 12/92 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

manzamine A : An alkaloid of the class of beta-carbolines isolated from Haliclona and Acanthostrongylophora. It exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	6509753
CHEMBL ID	326531
CHEMBL ID	403233
CHEBI ID	66667
SCHEMBL ID	14377624
MeSH ID	M0209906

Synonym
manzamine a
104196-68-1
manzamine
CHEMBL326531
chembl403233 ,
bdbm50232478
chebi:66667 ,
keramamine a
(4ar,7s,7ar,13z,14ar,15ar,18z)-5-(9h-beta-carbolin-1-yl)-4,4a,9,10,11,12,14a,15-octahydro-3h-7,2-oct[3]enoazocino[1',2':1,5]pyrrolo[2,3-i]isoquinolin-7(1h,7ah)-ol
SCHEMBL14377624
Q27135285
CS-0063523
HY-117025
(1r,4s,9z,13s,13ar,20ar,21ar)-2,3,5,6,7,8,11,12,15,16,17,18,20a,21-tetradecahydro-24-(9h-pyrido[3,4-b]indol-1-yl)-1,13-etheno-4,21a-methano-1h-azocino[1',2':1,5]pyrrolo[3,2-e]azacyclopentadecin-13(13ah)-ol
DTXSID001098329
AKOS040748872

Excerpt	Reference	Relevance
"The manzamine alkaloids are a unique class of alkaloids possessing a characteristic heterocyclic system, and exhibit a diverse range of bioactivities including cytotoxicity, antimicrobial activity, antimalarial activity, antiviral and antiinflammatory activities, antiinsecticidal activity, and proteasome inhibitory activity."	( The manzamine alkaloids. Kobayashi, J; Kubota, T; Kurimoto, SI, 2020)	1.6
"Manzamine A is a sponge-derived β-carboline-fused pentacyclic alkaloid with various bioactivities, including recently reported anticancer activity on pancreatic cancer."	( Manzamine A Exerts Anticancer Activity against Human Colorectal Cancer Cells. Chang, HY; Hsia, SM; Huang, TC; Kuo, TT; Lin, LC; Liu, WS, 2018)	2.64
"Manzamine A is a β-carboline alkaloid isolated from the Indo-Pacific sponge Acanthostrongylophora species."	( Discovery and preliminary structure-activity relationship of the marine natural product manzamines as herpes simplex virus type-1 inhibitors. Hsia, SV; Mudit, M; Palem, JR; Sayed, KAE, 2017)	1.18
"Manzamine A is an alkaloid isolated from marine sponges that was suspected to have inhibitory activity against the mitogen activated kinase kinase (MEK)."	( A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis. Gunasekera, SE; Guzmán, EA; Johnson, JD; Linley, PA; Wright, AE, 2011)	1.36

Excerpt	Reference	Relevance
"Manzamine A has recently been shown to exhibit in vivo antimalarial activity against parasite Plasmodium berghei."	( Recent developments in marine indole alkaloid synthesis. Akiba, M; Arisawa, M; Fuwa, M; Hatakeyama, K; Nagata, T; Nakagawa, M; Nishida, A; Ono, K; Uchida, H; Watanabe, T, 2003)	1.04

Excerpt	Reference	Relevance
"Treatment with manzamine A in combination with bafilomycin A1 (inhibitor of autophagosome-lysosome fusion) did not change the levels of LC3-II when compared to cells treated with bafilomycin A1 alone, suggesting that manzamine A is a potential inhibitor of autophagy by preventing autophagosome turnover."	( The marine natural product manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Guzmán, EA; Hoepfner, D; Jaeg, T; Kallifatidis, G; Wright, AE, 2013)	1.03

Excerpt	Reference	Relevance
" The potent antiinflammatory, antifungal, and anti-HIV-1 activity for a number of previously reported manzamines is also presented in addition to the pharmacokinetic studies of manzamine A (5)."	( New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. Charman, WN; Hamann, MT; Hammond, NL; Mayer, AM; McIntosh, KA; Peng, J; Wahyuono, S; Yousaf, M, 2004)	1.07

Excerpt	Reference	Relevance
" Oral and intravenous pharmacokinetic studies of manzamine A in rats indicated the compound to have low metabolic clearance, a reasonably long pharmacokinetic half-life, and good absolute oral bioavailability of 20."	( New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. Charman, WN; Hamann, MT; Hammond, NL; Mayer, AM; McIntosh, KA; Peng, J; Wahyuono, S; Yousaf, M, 2004)	1.14

Role	Description
antimalarial	A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
anti-HSV-1 agent	An anti-HSV agent agent that destroys or inhibits the replication of herpes simplex virus-1.
animal metabolite	Any eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
marine metabolite	Any metabolite produced during a metabolic reaction in marine macro- and microorganisms.
EC 2.7.11.26 (tau-protein kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of tau-protein kinase inhibitor (EC 2.7.11.26).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
beta-carbolines	Any pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
alkaloid	Any of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	IC50 (µMol)	4.8000	0.0320	1.4649	4.8000	AID754954
Sterol O-acyltransferase 2	Homo sapiens (human)	IC50 (µMol)	4.8000	0.1100	3.2036	9.2000	AID754954
Dipeptidyl peptidase 4	Homo sapiens (human)	IC50 (µMol)	10.2000	0.0001	0.4444	10.0000	AID340537
Sterol O-acyltransferase 1	Homo sapiens (human)	IC50 (µMol)	6.3000	0.0250	1.7975	8.0000	AID754955; AID754967
Glycogen synthase kinase-3 alpha	Homo sapiens (human)	IC50 (µMol)	25.0000	0.0010	1.2249	9.1000	AID340590
Glycogen synthase kinase-3 beta	Homo sapiens (human)	IC50 (µMol)	10.2167	0.0006	0.8013	10.0000	AID311304; AID340537; AID340589; AID430058; AID546577; AID718830
Cyclin-dependent-like kinase 5	Homo sapiens (human)	IC50 (µMol)	1.5000	0.0002	1.1832	10.0000	AID311307
Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)	IC50 (µMol)	1.5000	0.0010	1.2898	10.0000	AID311307
Class A sortase SrtA	Staphylococcus aureus	IC50 (µMol)	150.0000	0.3000	2.8600	5.9000	AID1491086
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cholesterol metabolic process	Sterol O-acyltransferase 2	Homo sapiens (human)
macrophage derived foam cell differentiation	Sterol O-acyltransferase 2	Homo sapiens (human)
cholesterol storage	Sterol O-acyltransferase 2	Homo sapiens (human)
intestinal cholesterol absorption	Sterol O-acyltransferase 2	Homo sapiens (human)
cholesterol efflux	Sterol O-acyltransferase 2	Homo sapiens (human)
very-low-density lipoprotein particle assembly	Sterol O-acyltransferase 2	Homo sapiens (human)
low-density lipoprotein particle clearance	Sterol O-acyltransferase 2	Homo sapiens (human)
cholesterol homeostasis	Sterol O-acyltransferase 2	Homo sapiens (human)
behavioral fear response	Dipeptidyl peptidase 4	Homo sapiens (human)
response to hypoxia	Dipeptidyl peptidase 4	Homo sapiens (human)
proteolysis	Dipeptidyl peptidase 4	Homo sapiens (human)
cell adhesion	Dipeptidyl peptidase 4	Homo sapiens (human)
positive regulation of cell population proliferation	Dipeptidyl peptidase 4	Homo sapiens (human)
negative regulation of extracellular matrix disassembly	Dipeptidyl peptidase 4	Homo sapiens (human)
peptide hormone processing	Dipeptidyl peptidase 4	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Dipeptidyl peptidase 4	Homo sapiens (human)
T cell costimulation	Dipeptidyl peptidase 4	Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrin	Dipeptidyl peptidase 4	Homo sapiens (human)
locomotory exploration behavior	Dipeptidyl peptidase 4	Homo sapiens (human)
psychomotor behavior	Dipeptidyl peptidase 4	Homo sapiens (human)
T cell activation	Dipeptidyl peptidase 4	Homo sapiens (human)
endothelial cell migration	Dipeptidyl peptidase 4	Homo sapiens (human)
symbiont entry into host cell	Dipeptidyl peptidase 4	Homo sapiens (human)
receptor-mediated virion attachment to host cell	Dipeptidyl peptidase 4	Homo sapiens (human)
negative chemotaxis	Dipeptidyl peptidase 4	Homo sapiens (human)
membrane fusion	Dipeptidyl peptidase 4	Homo sapiens (human)
negative regulation of neutrophil chemotaxis	Dipeptidyl peptidase 4	Homo sapiens (human)
glucagon processing	Dipeptidyl peptidase 4	Homo sapiens (human)
cholesterol metabolic process	Sterol O-acyltransferase 1	Homo sapiens (human)
cholesterol metabolic process	Sterol O-acyltransferase 1	Homo sapiens (human)
macrophage derived foam cell differentiation	Sterol O-acyltransferase 1	Homo sapiens (human)
cholesterol storage	Sterol O-acyltransferase 1	Homo sapiens (human)
cholesterol efflux	Sterol O-acyltransferase 1	Homo sapiens (human)
very-low-density lipoprotein particle assembly	Sterol O-acyltransferase 1	Homo sapiens (human)
low-density lipoprotein particle clearance	Sterol O-acyltransferase 1	Homo sapiens (human)
cholesterol homeostasis	Sterol O-acyltransferase 1	Homo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic process	Sterol O-acyltransferase 1	Homo sapiens (human)
regulation of systemic arterial blood pressure	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cardiac left ventricle morphogenesis	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
glycogen metabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
dopamine receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
nervous system development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
insulin receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of autophagy	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of UDP-glucose catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
Wnt signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cell migration	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
viral protein processing	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein ubiquitination	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of TOR signaling	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to insulin stimulus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to interleukin-3	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen biosynthetic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of heart contraction	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glucose import	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
excitatory postsynaptic potential	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to lithium ion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
autosome genomic imprinting	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of mitophagy	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of amyloid-beta formation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of protein targeting to mitochondrion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphate	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of type B pancreatic cell development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
negative regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cell differentiation	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
regulation of neuron projection development	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ER overload response	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-serine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
intracellular signal transduction	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of apoptotic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein export from nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
epithelial to mesenchymal transition	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Glycogen synthase kinase-3 beta	Homo sapiens (human)
glycogen metabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
mitochondrion organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dopamine receptor signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
circadian rhythm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of autophagy	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of gene expression	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-serine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
peptidyl-threonine phosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
viral protein processing	Glycogen synthase kinase-3 beta	Homo sapiens (human)
hippocampus development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
establishment of cell polarity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
maintenance of cell polarity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of cell migration	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of axon extension	Glycogen synthase kinase-3 beta	Homo sapiens (human)
neuron projection development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein ubiquitination	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of phosphoprotein phosphatase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule-based process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
intracellular signal transduction	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to interleukin-3	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of circadian rhythm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of GTPase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of osteoblast differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of glycogen biosynthetic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of cilium assembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein catabolic process	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein autophosphorylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of protein export from nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of dendrite morphogenesis	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of axonogenesis	Glycogen synthase kinase-3 beta	Homo sapiens (human)
canonical Wnt signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
excitatory postsynaptic potential	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascade	Glycogen synthase kinase-3 beta	Homo sapiens (human)
superior temporal gyrus development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to retinoic acid	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
extrinsic apoptotic signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligand	Glycogen synthase kinase-3 beta	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Glycogen synthase kinase-3 beta	Homo sapiens (human)
neuron projection organization	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of microtubule anchoring at centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of cellular response to heat	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein localization to nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of long-term synaptic potentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of protein acetylation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein localization to cilium	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of dopaminergic neuron differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cellular response to amyloid-beta	Glycogen synthase kinase-3 beta	Homo sapiens (human)
positive regulation of protein localization to centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin destruction complex disassembly	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of type B pancreatic cell development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of glycogen (starch) synthase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of mesenchymal stem cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
negative regulation of TOR signaling	Glycogen synthase kinase-3 beta	Homo sapiens (human)
regulation of neuron projection development	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cell differentiation	Glycogen synthase kinase-3 beta	Homo sapiens (human)
insulin receptor signaling pathway	Glycogen synthase kinase-3 beta	Homo sapiens (human)
microtubule cytoskeleton organization	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron migration	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic transmission, dopaminergic	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
intracellular protein transport	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cell-matrix adhesion	Cyclin-dependent-like kinase 5	Homo sapiens (human)
chemical synaptic transmission	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synapse assembly	Cyclin-dependent-like kinase 5	Homo sapiens (human)
skeletal muscle tissue development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
motor neuron axon guidance	Cyclin-dependent-like kinase 5	Homo sapiens (human)
visual learning	Cyclin-dependent-like kinase 5	Homo sapiens (human)
Schwann cell development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic vesicle exocytosis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of macroautophagy	Cyclin-dependent-like kinase 5	Homo sapiens (human)
phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
peptidyl-threonine phosphorylation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
sensory perception of pain	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cerebellar cortex formation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
hippocampus development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
layer formation in cerebral cortex	Cyclin-dependent-like kinase 5	Homo sapiens (human)
central nervous system neuron development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
corpus callosum development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron differentiation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of cell migration	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of axon extension	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron projection development	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of protein ubiquitination	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of synaptic plasticity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
receptor catabolic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic transmission, glutamatergic	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein localization to synapse	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of apoptotic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
receptor clustering	Cyclin-dependent-like kinase 5	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of cell cycle	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of proteolysis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cyclin-dependent-like kinase 5	Homo sapiens (human)
positive regulation of calcium ion-dependent exocytosis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
negative regulation of protein export from nucleus	Cyclin-dependent-like kinase 5	Homo sapiens (human)
behavioral response to cocaine	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of synaptic plasticity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic vesicle endocytosis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
rhythmic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
axon extension	Cyclin-dependent-like kinase 5	Homo sapiens (human)
oligodendrocyte differentiation	Cyclin-dependent-like kinase 5	Homo sapiens (human)
dendrite morphogenesis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cell division	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron apoptotic process	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of cell cycle	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Cyclin-dependent-like kinase 5	Homo sapiens (human)
excitatory postsynaptic potential	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of dendritic spine morphogenesis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
calcium ion import	Cyclin-dependent-like kinase 5	Homo sapiens (human)
positive regulation of protein targeting to membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of protein localization to plasma membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of synaptic vesicle recycling	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cellular response to amyloid-beta	Cyclin-dependent-like kinase 5	Homo sapiens (human)
axonogenesis	Cyclin-dependent-like kinase 5	Homo sapiens (human)
synaptic vesicle transport	Cyclin-dependent-like kinase 5	Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
microtubule cytoskeleton organization	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
neuron migration	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
neuron cell-cell adhesion	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
axon guidance	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
axonal fasciculation	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
brain development	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
embryo development ending in birth or egg hatching	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
regulation of macroautophagy	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
cerebellum development	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
superior olivary nucleus maturation	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
hippocampus development	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
layer formation in cerebral cortex	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
neuron differentiation	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
positive regulation of microtubule polymerization	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
neuron projection development	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
regulation of actin cytoskeleton organization	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
regulation of neuron differentiation	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
ephrin receptor signaling pathway	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
rhythmic process	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
regulation of dendritic spine morphogenesis	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
G1 to G0 transition involved in cell differentiation	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
positive regulation of protein targeting to membrane	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
regulation of synaptic vesicle cycle	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
fatty-acyl-CoA binding	Sterol O-acyltransferase 2	Homo sapiens (human)
sterol O-acyltransferase activity	Sterol O-acyltransferase 2	Homo sapiens (human)
protein binding	Sterol O-acyltransferase 2	Homo sapiens (human)
cholesterol binding	Sterol O-acyltransferase 2	Homo sapiens (human)
acyltransferase activity	Sterol O-acyltransferase 2	Homo sapiens (human)
cholesterol O-acyltransferase activity	Sterol O-acyltransferase 2	Homo sapiens (human)
virus receptor activity	Dipeptidyl peptidase 4	Homo sapiens (human)
protease binding	Dipeptidyl peptidase 4	Homo sapiens (human)
aminopeptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
serine-type endopeptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
signaling receptor binding	Dipeptidyl peptidase 4	Homo sapiens (human)
protein binding	Dipeptidyl peptidase 4	Homo sapiens (human)
serine-type peptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
dipeptidyl-peptidase activity	Dipeptidyl peptidase 4	Homo sapiens (human)
identical protein binding	Dipeptidyl peptidase 4	Homo sapiens (human)
protein homodimerization activity	Dipeptidyl peptidase 4	Homo sapiens (human)
chemorepellent activity	Dipeptidyl peptidase 4	Homo sapiens (human)
fatty-acyl-CoA binding	Sterol O-acyltransferase 1	Homo sapiens (human)
sterol O-acyltransferase activity	Sterol O-acyltransferase 1	Homo sapiens (human)
protein binding	Sterol O-acyltransferase 1	Homo sapiens (human)
cholesterol binding	Sterol O-acyltransferase 1	Homo sapiens (human)
cholesterol O-acyltransferase activity	Sterol O-acyltransferase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
signaling receptor binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
ATP binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein kinase A catalytic subunit binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
tau protein binding	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
tau-protein kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protein serine kinase activity	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
protease binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
p53 binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein serine/threonine kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ATP binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
ubiquitin protein ligase binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein kinase A catalytic subunit binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dynactin binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
tau protein binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
tau-protein kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
NF-kappaB binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Glycogen synthase kinase-3 beta	Homo sapiens (human)
protein serine kinase activity	Glycogen synthase kinase-3 beta	Homo sapiens (human)
microtubule binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
p53 binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein serine/threonine kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
ErbB-2 class receptor binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
ATP binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
acetylcholine receptor activator activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
ErbB-3 class receptor binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
tau protein binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
tau-protein kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
Hsp90 protein binding	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein serine kinase activity	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protease binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
protein kinase activity	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
calcium ion binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
protein binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
kinase activity	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
protein kinase binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
protein kinase activator activity	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
ionotropic glutamate receptor binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
alpha-tubulin binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
protein serine/threonine kinase activator activity	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
cadherin binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
ephrin receptor binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
beta-tubulin binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
actin filament binding	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activity	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endoplasmic reticulum	Sterol O-acyltransferase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Sterol O-acyltransferase 2	Homo sapiens (human)
brush border	Sterol O-acyltransferase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Sterol O-acyltransferase 2	Homo sapiens (human)
extracellular region	Dipeptidyl peptidase 4	Homo sapiens (human)
lysosomal membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
plasma membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
focal adhesion	Dipeptidyl peptidase 4	Homo sapiens (human)
cell surface	Dipeptidyl peptidase 4	Homo sapiens (human)
membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
apical plasma membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
lamellipodium	Dipeptidyl peptidase 4	Homo sapiens (human)
endocytic vesicle	Dipeptidyl peptidase 4	Homo sapiens (human)
lamellipodium membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
membrane raft	Dipeptidyl peptidase 4	Homo sapiens (human)
intercellular canaliculus	Dipeptidyl peptidase 4	Homo sapiens (human)
extracellular exosome	Dipeptidyl peptidase 4	Homo sapiens (human)
plasma membrane	Dipeptidyl peptidase 4	Homo sapiens (human)
endoplasmic reticulum	Sterol O-acyltransferase 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sterol O-acyltransferase 1	Homo sapiens (human)
membrane	Sterol O-acyltransferase 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sterol O-acyltransferase 1	Homo sapiens (human)
mitochondrion	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
beta-catenin destruction complex	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
neuronal cell body	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
apical dendrite	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
postsynapse	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
proximal dendrite	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
axon	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 alpha	Homo sapiens (human)
glutamatergic synapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
mitochondrion	Glycogen synthase kinase-3 beta	Homo sapiens (human)
centrosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 beta	Homo sapiens (human)
plasma membrane	Glycogen synthase kinase-3 beta	Homo sapiens (human)
axon	Glycogen synthase kinase-3 beta	Homo sapiens (human)
dendrite	Glycogen synthase kinase-3 beta	Homo sapiens (human)
beta-catenin destruction complex	Glycogen synthase kinase-3 beta	Homo sapiens (human)
presynapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
postsynapse	Glycogen synthase kinase-3 beta	Homo sapiens (human)
Wnt signalosome	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytosol	Glycogen synthase kinase-3 beta	Homo sapiens (human)
axon	Glycogen synthase kinase-3 beta	Homo sapiens (human)
nucleus	Glycogen synthase kinase-3 beta	Homo sapiens (human)
cytoplasm	Glycogen synthase kinase-3 beta	Homo sapiens (human)
microtubule	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent-like kinase 5	Homo sapiens (human)
nucleus	Cyclin-dependent-like kinase 5	Homo sapiens (human)
nucleoplasm	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cytoplasm	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cytosol	Cyclin-dependent-like kinase 5	Homo sapiens (human)
plasma membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
postsynaptic density	Cyclin-dependent-like kinase 5	Homo sapiens (human)
membrane	Cyclin-dependent-like kinase 5	Homo sapiens (human)
protein kinase 5 complex	Cyclin-dependent-like kinase 5	Homo sapiens (human)
lamellipodium	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cell junction	Cyclin-dependent-like kinase 5	Homo sapiens (human)
filopodium	Cyclin-dependent-like kinase 5	Homo sapiens (human)
axon	Cyclin-dependent-like kinase 5	Homo sapiens (human)
dendrite	Cyclin-dependent-like kinase 5	Homo sapiens (human)
growth cone	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuromuscular junction	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuron projection	Cyclin-dependent-like kinase 5	Homo sapiens (human)
neuronal cell body	Cyclin-dependent-like kinase 5	Homo sapiens (human)
perikaryon	Cyclin-dependent-like kinase 5	Homo sapiens (human)
presynapse	Cyclin-dependent-like kinase 5	Homo sapiens (human)
nucleus	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cytoplasm	Cyclin-dependent-like kinase 5	Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complex	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
nucleus	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
nucleoplasm	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
cytosol	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
plasma membrane	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
postsynaptic density	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
membrane	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
protein kinase 5 complex	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
axon	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
dendrite	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
growth cone	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
neuromuscular junction	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
neuron projection	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
neuronal cell body	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
dendritic spine	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
perikaryon	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
intracellular membrane-bounded organelle	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
contractile muscle fiber	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
perinuclear region of cytoplasm	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
presynapse	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
cytoplasm	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
growth cone	Cyclin-dependent kinase 5 activator 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (393)

Assay ID	Title	Year	Journal	Article
AID355989	Antimalarial activity against Plasmodium falciparum D6	2003	Journal of natural products, Jun, Volume: 66, Issue:6	New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge.
AID461632	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) at 10 mg/kg, intraperitoneally for 3 days administered 1 day after infection measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647722	Inhibition of colony formation in human HeLa cells at 2 to 4 uM afer 1 week by crystal violet staining based assay
AID1647737	Cell cycle arrest in human C33A cells assessed as accumulation at G0/G1 phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 54.6%)
AID377704	Antifungal activity against Cryptococcus neoformans	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID355068	Insecticidal activity against Spodoptera littoralis neonate larvae assessed as inhibition of larval growth at 132 ppm administered with artificial diet after 6 days by chronic feeding experiment relative to control	1996	Journal of natural products, Nov, Volume: 59, Issue:11	Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica.
AID461353	Antifungal activity against Cryptococcus neoformans ATCC 90113	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461625	Antiplasmodial activity against Plasmodium berghei infected in mice (Mus musculus) at 5 mg/kg, subcutaneously administered 1 day post infection for 3 days	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647825	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human SiHa cells after 48 hrs by Western blot analysis
AID1647720	Antiproliferative activity against human CaSki cells assessed as reduction in cell viability by CellTiter-Glo assay
AID1647715	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay
AID1601819	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv	2019	European journal of medicinal chemistry, Mar-01, Volume: 165	Marine natural products as potential anti-tubercular agents.
AID461624	Antiplasmodial activity against Plasmodium berghei infected in mice (Mus musculus) at 5 mg/kg, perorally administered 1 day post infection for 3 days	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340596	Antimicrobial activity against Candida albicans ATCC 90028	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID1647799	Inhibition of Human papillomavirus type16 derived E6 in human CaSki cells assessed as increase in p53 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID1647798	Inhibition of Human papillomavirus type16 derived E7 in human SiHa cells assessed as decrease in phosphorylation of Rb at 2 to 4 uM after 48 hrs by Western blot analysis
AID340546	Antimicrobial activity against Cryptococcus neoformans ATCC 90113	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID377705	Antibacterial activity against Mycobacterium intracellular by alamar blue assay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID333079	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID461381	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1316812	Cytotoxicity against human NCI-H1993 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID461588	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as survivability at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID377698	Antileishmanial activity against Leishmania donovani after 72 hrs by alamar blue assay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID461610	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 100 mg/kg, perorally administered 1 day after infection measured after 21 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340537	Inhibition of human GSK3-beta	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID333073	Cytotoxicity against african green monkey Vero cells	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID377706	Antiviral activity against HIV1 3B assessed as reverse transcriptase activity by enzyme immunoassay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1647752	Cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 69.6%)
AID452161	Cytotoxicity against african green monkey Vero cells by neutral red assay	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID1647742	Cell cycle arrest in human SiHa cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 69.9%)
AID340599	Antimicrobial activity against Mycobacterium intracellular ATCC 23068	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID1647712	Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
AID452168	Antifungal activity against Cryptococcus neoformans by modified NCCLS method	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID461607	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 100 mg/kg, perorally administered 1 day after infection measured after 14 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340600	Antimalarial activity as reduced parasitaemia day 7 in Plasmodium berghei NK65 infected mice (Mus musculus) at 10 mg/kg peroral dose three times daily 2 days post infection	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID452158	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID340553	Antimicrobial activity against Mycobacterium intracellular ATCC 23068	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID377710	Inhibition of human recombinant GSK3-beta assessed as incorporation of [33P]gammaATP into G2S peptide at 25 uM	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1647777	Induction of apoptosis in human HeLa cells assessed as viable cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 80.7%)
AID461342	Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461371	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 10 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID333072	Antileishmanial activity against Leishmania donovani	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID340595	Antileishmanial activity against Leishmania donovani promastigotes after 72 hrs by almar blue assay	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID1647739	Cell cycle arrest in human C33A cells assessed as accumulation at Sub G1 phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 0.7%)
AID1647780	Induction of apoptosis in human CaSki cells assessed as viable cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 84%)
AID1647787	Cell cycle arrest in human SiHa cells assessed as increase in accumulation at G0/G1 phase at 4 uM incubated for 24 hrs by by propidium iodide staining based flow cytometric analysis
AID461591	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647710	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
AID1316809	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID333009	Cytotoxicity against human LoVo cells	1994	Journal of natural products, Jan, Volume: 57, Issue:1	8-Hydroxymanzamine A, a beta-carboline alkaloid from a sponge, Pachypellina sp.
AID1647781	Induction of apoptosis in human CaSki cells assessed as early apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 12.2%)
AID461351	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID754952	Inhibition of microsomal ACAT in apoE-deficient mouse peritoneal macrophage using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs by TLC analysis	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461878	Cell cycle arrest in human HeLa cells assessed as decrease in G2/M phase accumulation at 20 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647763	Induction of apoptosis in human C33A cells assessed as viable cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 93.3%)
AID461872	Cell cycle arrest in human HeLa cells assessed as increase in S phase accumulation at 5 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647741	Cell cycle arrest in human C33A cells assessed as accumulation at G2/M phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 25.2%)
AID1647753	Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 16.2%)
AID754964	Cytotoxicity against human MDM assessed as change in cell morphology at 50 uM	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID377714	Toxicity against medaka fry after 96 hrs	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1866010	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Isolation and biological activity of azocine and azocane alkaloids.
AID754954	Non-competitive inhibition of human microsomal ACAT2 overexpressed in CHO cells using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID355997	Antiviral activity against HIV1 in human PBM cells	2003	Journal of natural products, Jun, Volume: 66, Issue:6	New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge.
AID461637	Cell cycle arrest in human HeLa cells assessed as increase in G0/G1 phase accumulation at 3 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461593	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461609	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 50 mg/kg, perorally administered 1 day after infection measured after 21 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461374	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 14 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461606	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 50 mg/kg, perorally administered 1 day after infection measured after 14 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1316810	Cytotoxicity against human NCI-H1299 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID754965	Antihyperlipidemic activity in human MDM assessed as inhibition of acetylated LDL-induced [3H]-cholesterol ester accumulation after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461352	Antifungal activity against Candida albicans ATCC 90028	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID452167	Antifungal activity against Candida albicans after 24 hrs by alamar blue assay	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID1647764	Induction of apoptosis in human C33A cells assessed as early apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 4.3%)
AID461596	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647751	Cell cycle arrest in human HeLa cells assessed as accumulation at Sub G1 phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 2.1%)
AID340590	Inhibition of GSK3alpha	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID1647721	Inhibition of colony formation in human C33A cells at 2 to 4 uM afer 1 week by crystal violet staining based assay
AID377703	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID377700	Cytotoxicity against african green monkey Vero cells by neutral red assay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID461613	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 100 mg/kg, perorally administered 1 day after infection measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461368	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 10 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647779	Induction of apoptosis in human HeLa cells assessed as late apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 4.4%)
AID1491085	Inhibition of KCl-stimulated Na+/K+-ATPase in human placental membrane vesicles measured for 60 secs by 3-O-methylfluorescein phosphate dye based fluorometric method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID1647793	Induction of apoptosis in human SiHa cells assessed as apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 6.4%)
AID1647789	Cell cycle arrest in human SiHa cells assessed as increase in accumulation at G0/G1 phase at 4 uM incubated for 48 hrs by by propidium iodide staining based flow cytometric analysis
AID461867	Cytotoxicity against human HeLa cells after 48 hrs by trypan blue exclusion assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647831	Toxicity in po dosed rat
AID461386	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) at 10 mg/kg, po	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1158607	Cytotoxicity against human HeLa cells after 3 days by MTT assay	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Acantholactam and pre-neo-kauluamine, manzamine-related alkaloids from the Indonesian marine sponge Acanthostrongylophora ingens.
AID1316819	Induction of autophagy in human NCI-H1299 cells transfected with GFP-LC3 assessed as increase in LC3-2 level at 3 to 10 uM after 24 hr by DAPI staining based immunofluorescence assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID1647823	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human HeLa cells after 48 hrs by Western blot analysis
AID1647784	Induction of apoptosis in human CaSki cells assessed as late apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 9.1%)
AID452166	Antifungal activity against Candida albicans by modified NCCLS method	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID461384	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) at 1.1 mg/kg, po	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647723	Inhibition of colony formation in human SiHa cells at 2 to 4 uM afer 1 week by crystal violet staining based assay
AID1647814	Inhibition of CK2alpha in human CaSki cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID1647713	Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay
AID340545	Antimicrobial activity against Candida albicans ATCC 90028 at 91 uM	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID461590	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID355071	Antibacterial activity against Staphylococcus aureus ATCC 25923 at 100 ug after 24 hrs by agar plate diffusion assay	1996	Journal of natural products, Nov, Volume: 59, Issue:11	Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica.
AID1647709	Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
AID461873	Cell cycle arrest in human HeLa cells assessed as increase in S phase accumulation at 10 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461380	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647790	Cell cycle arrest in human CaSki cells assessed as increase in accumulation at G0/G1 phase at 4 uM incubated for 48 hrs by by propidium iodide staining based flow cytometric analysis
AID452159	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID754962	Inhibition of endocytic [125I]-acetylated LDL uptake in human MDM at 50 uM after 5 hrs	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID1647811	Inhibition of SIX1 in human CaSki cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID461361	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID754961	Cytotoxicity against human MDM assessed as cell viability at 50 uM after 24 hrs by WST-8 assay	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461379	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 21 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340598	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID461868	Cell cycle arrest in human HeLa cells assessed as increase in G0/G1 phase accumulation at 5 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647767	Induction of apoptosis in human C33A cells assessed as early apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 12.9%)
AID461343	Antimycobacterial activity against Mycobacterium tuberculosis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647791	Induction of apoptosis in human C33A cells assessed as apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 17.3%)
AID754966	Antihyperlipidemic activity in human MDM assessed as inhibition of acetylated LDL-induced [3H]-cholesterol ester accumulation at 20 uM after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461357	Antineuroinflammatory activity in LPS-stimulated rat neonatal microglia assessed as drug level causing 50% PMA-induced LDH release preincubated 15 mins prior to PMA challenge measured after 70 mins	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1866008	Antibacterial activity against Staphylococcus aureus assessed as bacterial growth inhibition	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Isolation and biological activity of azocine and azocane alkaloids.
AID340535	Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID377708	Inhibition of human recombinant BACE1 by FRET-based assay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1647803	Effect on total-Rb in human CaSki cells assessed decrease in Rb protein level at 2 to 4 uM after 48 hrs by Western blot analysis
AID377692	Antituberculosis activity against Mycobacterium tuberculosis H37Rv after 24 hrs by alamar blue assay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID461626	Antiplasmodial activity against Plasmodium berghei infected in mice (Mus musculus) at 10 mg/kg, perorally administered 1 day post infection for 3 days	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID328109	Antibacterial activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay	2008	Journal of natural products, Mar, Volume: 71, Issue:3	Semisynthetic studies on the manzamine alkaloids.
AID461586	Antiplasmodial activity in Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as survivability at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647765	Induction of apoptosis in human C33A cells assessed as necrotic cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis
AID754956	Effect on ACAT expression in human MDM at 5 to 30 uM after 24 hrs by immunoblot analysis	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461344	Antibacterial activity against Staphylococcus aureus	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340593	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID1647770	Induction of apoptosis in human SiHa cells assessed as viable cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 90.8%)
AID1491084	Cytotoxicity against human A549 cells by MTT assay	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID1647813	Inhibition of CK2alpha in human SiHa cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID1316814	Cytotoxicity against human IMR90 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID1647806	Cell cycle arrest in human C33A cells assessed as increase in p53 protein expression at 2 to 4 uM after 48 hr by Western lot analysis
AID754950	Antiatherosclerotic activity in apoE-deficient C57BL/6 mouse assessed as decrease in plasma free cholesterol level at 30 mg/kg/day administered through feeding measured after 80 days relative to control	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID1647714	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay
AID340601	Antimalarial activity as reduced parasitaemia on day 10 in Plasmodium berghei NK65 infected mice (Mus musculus) at 10 mg/kg peroral dose three times daily for 2 days post infection	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID401054	Cytotoxicity against mouse L1210 cells	1998	Journal of natural products, May, Volume: 61, Issue:5	Three new manzamine congeners from amphimedon sponge
AID333010	Cytotoxicity against mouse P388 cells	1994	Journal of natural products, Jan, Volume: 57, Issue:1	8-Hydroxymanzamine A, a beta-carboline alkaloid from a sponge, Pachypellina sp.
AID1491077	Antibacterial activity against Staphylococcus aureus ATCC 6538p after 24 hrs by serial two fold dilution method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID1316808	Cytotoxicity against human NCI-H441 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID754960	Effect on scavenger receptor-B1 expression in human MDM at 5 to 30 uM after 24 hrs by immunoblot analysis	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID340539	Selectivity index, ratio of IC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-resistant Plasmodium falciparum W2	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID461603	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 50 mg/kg, perorally administered 1 day after infection measured after 10 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647719	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability by CellTiter-Glo assay
AID1647773	Induction of apoptosis in human SiHa cells assessed as early apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 2.4%)
AID340551	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 at 91 uM	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID461595	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 100 mg/kg, perorally administered 1 day after infection measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461634	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) assessed as weight loss at 10 mg/kg, intraperitoneally administered 1 day after infection measured after 3 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647775	Induction of apoptosis in human HeLa cells assessed as viable cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 85.2%)
AID461378	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 21 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340597	Antimicrobial activity against Cryptococcus neoformans ATCC 90113	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID461616	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 100 mg/kg, perorally administered 1 day after infection measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461611	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 21 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID311309	Inhibition of recombinant PKA	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
AID1647796	Inhibition of Human papillomavirus type16 derived E6 in human SiHa cells assessed as increase in p21 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID1647756	Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 12.6%)
AID311307	Inhibition of human recombinant CDK5/p35	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
AID1647776	Induction of apoptosis in human HeLa cells assessed as early apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 6.3%)
AID1647824	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human C33A cells after 48 hrs by Western blot analysis
AID461870	Cell cycle arrest in human HeLa cells assessed as increase in G0/G1 phase accumulation at 20 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID754948	Antiatherosclerotic activity in apoE-deficient C57BL/6 mouse assessed as decrease in plasma triglyceride level at 30 mg/kg/day administered through feeding measured after 80 days relative to control	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID1647744	Cell cycle arrest in human SiHa cells assessed as accumulation at G0/G1 phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 72.7%)
AID1647768	Induction of apoptosis in human C33A cells assessed as late apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 2.5%)
AID333071	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID461592	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461383	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID377716	Selectivity ratio of LD50 for medaka fry to ED50 for medaka eggs	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID461614	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461623	Antiplasmodial activity against Plasmodium yoelii infected in perorally dosed mice (Mus musculus)	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID430058	Inhibition of recombinant GSK3-beta by ELISA	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.
AID1491079	Antibacterial activity against Kocuria rhizophila NBRC 12708 after 24 hrs by serial two fold dilution method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID377709	Blocking of calcium channel in human SH-SY5Y cells assessed as inhibition of KCL depolarization-induced cytosolic calcium increase at 1 uM	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1647711	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay
AID1866007	Cytotoxicity against mouse P388 cells assessed as cell growth inhibition	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Isolation and biological activity of azocine and azocane alkaloids.
AID461356	Antineuroinflammatory activity in LPS-stimulated rat neonatal microglia assessed as inhibition of PMA-induced TXB2 production preincubated 15 mins prior to PMA challenge measured after 70 mins	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID754957	Antihyperlipidemic activity in CHO cells overexpressing human ACAT2 assessed as inhibition of [3H]-cholesterol ester accumulation after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID340592	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 by LDH activity	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID1647778	Induction of apoptosis in human HeLa cells assessed as early apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 10.7%)
AID333011	Antiviral activity against HSV2	1994	Journal of natural products, Jan, Volume: 57, Issue:1	8-Hydroxymanzamine A, a beta-carboline alkaloid from a sponge, Pachypellina sp.
AID333008	Cytotoxicity against human KB cells	1994	Journal of natural products, Jan, Volume: 57, Issue:1	8-Hydroxymanzamine A, a beta-carboline alkaloid from a sponge, Pachypellina sp.
AID1647717	Antiproliferative activity against human C33A cells assessed as reduction in cell viability by CellTiter-Glo assay
AID340557	Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID377696	Antimalarial activity after 72 hrs against chloroquine-resistant Plasmodium falciparum W2 in erythrocytes by LDH reporter assay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1647729	Effect on total-Rb in human SiHa cells assessed decrease in Rb protein level at 2 to 4 uM after 48 hrs by Western blot analysis
AID1158608	Inhibition of chymotrypsin-like activity of rat liver proteasome using fluorogenic substrates for 6 hrs	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Acantholactam and pre-neo-kauluamine, manzamine-related alkaloids from the Indonesian marine sponge Acanthostrongylophora ingens.
AID1647795	Inhibition of Human papillomavirus type16 derived E6 in human SiHa cells assessed as increase in p53 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID461369	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 10 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461358	Efflux ratio of apparent permeability from apical to basolateral side over basolateral to apical side in MDCK cells expressing MDR at 50 uM	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647786	Cell cycle arrest in human SiHa cells assessed as decrease in accumulation at S phase at 4 uM incubated up to 72 hrs by by propidium iodide staining based flow cytometric analysis
AID340589	Inhibition of GSK3-beta	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID1846860	Antimalarial activity against Plasmodium falciparum D6	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Structure activity relationship in β-carboline derived anti-malarial agents.
AID754959	Effect on scavenger receptor-A expression in human MDM at 5 to 30 uM after 24 hrs by immunoblot analysis	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID1647828	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of SIX1 in human SiHa cells after 48 hrs by Western blot analysis
AID461621	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) at 10 mg/kg, intraperitoneally administered 1 day after infection for 3 days	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1866009	Antiplasmodial activity against Plasmodium berghei infected in ip dosed Swiss albino mouse assessed as growth inhibition at asexual erythrocytic stage	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Isolation and biological activity of azocine and azocane alkaloids.
AID461615	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 50 mg/kg, perorally administered 1 day after infection measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461345	Antibacterial activity against methicillin-resistant Staphylococcus aureus	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340556	Antimicrobial activity against Escherichia coli ATCC 35218	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID1491080	Antibacterial activity against Salmonella enterica ATCC 14028 after 24 hrs by serial two fold dilution method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID452162	Therapeutic index, ratio of TC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6 infected in african green monkey (Cercopithecus aethiops) Vero cells	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID461599	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID355992	Cytotoxicity against african green monkey Vero cells	2003	Journal of natural products, Jun, Volume: 66, Issue:6	New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge.
AID1647762	Cell cycle arrest in human CaSki cells assessed as accumulation at G2/M phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 15.2%)
AID461347	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 after 72 hrs by LDH assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID397145	Cytotoxicity against mouse EL-4.IL-2 cells after 3 to 4 days by Trypan blue exclusion test	1993	Journal of natural products, Jun, Volume: 56, Issue:6	Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID1647808	Inhibition of SIX1 in human C33A cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID1647785	Cell cycle arrest in human CaSki cells assessed as decrease in accumulation at S phase at 4 uM incubated up to 72 hrs by by propidium iodide staining based flow cytometric analysis
AID461370	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 10 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647733	Cell cycle arrest in human C33A cells assessed as accumulation at Sub G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 0.7%)
AID340558	Antimicrobial activity against Aspergillus fumigatus ATCC 90906	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID461602	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 7 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647716	Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay
AID340536	Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 as LDH activity	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID1647794	Induction of apoptosis in human CaSki cells assessed as apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 18.4.4%)
AID1647706	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay
AID1647783	Induction of apoptosis in human CaSki cells assessed as early apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 4.4%)
AID461628	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) assessed as weight loss after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID340540	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID1647788	Cell cycle arrest in human CaSki cells assessed as increase in accumulation at G0/G1 phase at 4 uM incubated for 24 hrs by by propidium iodide staining based flow cytometric analysis
AID1647757	Cell cycle arrest in human CaSki cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 56%)
AID397144	Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay	1993	Journal of natural products, Jun, Volume: 56, Issue:6	Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID333069	Antitubercular activity against Mycobacterium tuberculosis H37Rv	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID1647743	Cell cycle arrest in human SiHa cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 17%)
AID1647755	Cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 76.4%)
AID355991	Antileishmanial activity against Leishmania donovani promastigotes expressing luciferase	2003	Journal of natural products, Jun, Volume: 66, Issue:6	New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge.
AID311306	Inhibition of recombinant GSKalpha	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
AID328113	Antiinflammatory activity in Escherichia coli lipopolysaccharide-activated rat neonatal microglia assessed as inhibition of eicosanoid thromboxane B2	2008	Journal of natural products, Mar, Volume: 71, Issue:3	Semisynthetic studies on the manzamine alkaloids.
AID461348	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647797	Inhibition of Human papillomavirus type16 derived E7 in human SiHa cells assessed as decrease in cyclin-D1 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID461601	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 100 mg/kg, perorally administered 1 day after infection measured after 7 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647804	Inhibition of Human papillomavirus type18 derived E6 in human HeLa cells assessed as increase in p53 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID1647718	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by CellTiter-Glo assay
AID355070	Antibacterial activity against Bacillus subtilis 168 at 100 ug after 24 hrs by agar plate diffusion assay	1996	Journal of natural products, Nov, Volume: 59, Issue:11	Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica.
AID340542	Antimicrobial activity against Candida albicans ATCC 90028	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID1316813	Cytotoxicity against human NCI-H2009 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID1647758	Cell cycle arrest in human CaSki cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 27.4%)
AID1647800	Inhibition of Human papillomavirus type16 derived E6 in human CaSki cells assessed as increase in p21 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID333070	Antimalarial activity against Plasmodium falciparum D6	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID461622	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 10 mg/kg, intraperitoneally administered 1 day after infection measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID333078	Antimicrobial activity against Staphylococcus aureus	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID340533	Antimalarial activity after 72 hrs against chloroquine-resistant Plasmodium falciparum W2 as LDH activity	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID461871	Cell cycle arrest in human HeLa cells assessed as increase in S phase accumulation at 3 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647827	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of SIX1 in human HeLa cells after 48 hrs by Western blot analysis
AID461587	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as survivability at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID754958	Antihyperlipidemic activity in CHO cells overexpressing human ACAT1 assessed as inhibition of [3H]-cholesterol ester accumulation after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID1647829	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of SIX1 in human C33A cells after 48 hrs by Western blot analysis
AID1647771	Induction of apoptosis in human SiHa cells assessed as early apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 5.4%)
AID340591	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 as LDH activity	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID461880	Inhibition of pig brain tubulin polymerization after 30 to 60 mins in presence of GTP and glutamate by turbidimetry	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647782	Induction of apoptosis in human CaSki cells assessed as viable cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 81.6%)
AID1647724	Inhibition of colony formation in human CaSki cells at 2 to 4 uM afer 1 week by crystal violet staining based assay
AID461359	Apparent permeability across apical to basolateral side of MDCK cells expressing MDR	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647735	Cell cycle arrest in human C33A cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 26.2%)
AID754967	Non-competitive inhibition of microsomal ACAT in human MDM using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID1846861	Antimalarial activity against Plasmodium falciparum W2	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Structure activity relationship in β-carboline derived anti-malarial agents.
AID718830	Non-ATP competitive inhibition of GSK3beta	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
AID461618	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as suppression of parasitaemia at 10 mg/kg, intraperitoneally administered 1 day after infection for 3 days measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461877	Cell cycle arrest in human HeLa cells assessed as decrease in G2/M phase accumulation at 10 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID754947	Antiatherosclerotic activity in apoE-deficient C57BL/6 mouse assessed as decrease in atherosclerotic lesion size in aortic sinus at 30 mg/kg/day administered through feeding measured after 80 days by oil red O/hematoxylin staining assay relative to contro	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID1647740	Cell cycle arrest in human C33A cells assessed as accumulation at G0/G1 phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 60%)
AID461600	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 50 mg/kg, perorally administered 1 day after infection measured after 7 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647750	Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 16.4%)
AID461364	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 7 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647708	Antiproliferative activity against human CaSki cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay
AID754953	Antihyperlipidemic activity in apoE-deficient mouse peritoneal macrophages assessed as inhibition of acetylated LDL-induced [3H]-cholesterol ester accumulation after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461605	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 10 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461365	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 7 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647754	Cell cycle arrest in human HeLa cells assessed as accumulation at Sub G1 phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 3.5%)
AID461633	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) at 3 mg/kg, intraperitoneally administered as 10 doses measured after 3 days of inoculation	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461612	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 50 mg/kg, perorally administered 1 day after infection measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1491078	Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by serial two fold dilution method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID1647809	Inhibition of SIX1 in human SiHa cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID355073	Cytotoxicity against mouse L5178Y cells after 72 hrs by MTT assay	1996	Journal of natural products, Nov, Volume: 59, Issue:11	Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica.
AID461869	Cell cycle arrest in human HeLa cells assessed as increase in G0/G1 phase accumulation at 10 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647761	Cell cycle arrest in human CaSki cells assessed as accumulation at G0/G1 phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 77.6%)
AID754949	Antiatherosclerotic activity in apoE-deficient C57BL/6 mouse assessed as decrease in plasma LDL cholesterol level at 30 mg/kg/day administered through feeding measured after 80 days relative to control	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461875	Cell cycle arrest in human HeLa cells assessed as decrease in G2/M phase accumulation at 3 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461367	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 7 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID401055	Antibacterial activity against Corynebacterium xerosis	1998	Journal of natural products, May, Volume: 61, Issue:5	Three new manzamine congeners from amphimedon sponge
AID1647769	Induction of apoptosis in human C33A cells assessed as necrotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 1.9%)
AID754955	Non-competitive inhibition of human microsomal ACAT1 overexpressed in CHO cells using [14C]oleoyl-CoA as substrate assessed as formation of cholesteryl [14C]-oleate after 24 hrs	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID311305	Inhibition of human recombinant GSKbeta at 25 uM	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
AID461360	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647792	Induction of apoptosis in human HeLa cells assessed as apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 19.3%)
AID333082	Antiviral activity against HIV1 infected in human PBMCs	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID1647801	Inhibition of Human papillomavirus type16 derived E7 in human CaSki cells assessed as decrease in cyclin-D1 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID754951	Antiatherosclerotic activity in apoE-deficient C57BL/6 mouse assessed as decrease in total plasma cholesterol level at 30 mg/kg/day administered through feeding measured after 80 days relative to control	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID311304	Inhibition of human recombinant GSKbeta	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
AID1647746	Cell cycle arrest in human SiHa cells assessed as accumulation at G0/G1 phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 72.8%)
AID461879	Inhibition of pig brain tubulin polymerization up to 30 mins by turbidimetry	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647734	Cell cycle arrest in human C33A cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 58.4%)
AID1647738	Cell cycle arrest in human C33A cells assessed as accumulation at G2/M phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 26.7%)
AID461876	Cell cycle arrest in human HeLa cells assessed as decrease in G2/M phase accumulation at 5 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1491083	Cytotoxicity against human K562 cells by MTT assay	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID1647707	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay
AID377694	Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 in erythrocytes by LDH reporter assay	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID452163	Therapeutic index, ratio of TC50 for african green monkey (Cercopithecus aethiops) Vero cells to IC50 for chloroquine-resistant Plasmodium falciparum W2 infected in african green monkey (Cercopithecus aethiops) Vero cells	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID1647812	Inhibition of CK2alpha in human HeLa cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID1647805	Inhibition of Human papillomavirus type18 derived E6 in human HeLa cells assessed as increase in p21 protein expression at 2 to 4 uM after 48 hrs by Western blot analysis
AID333081	Antibacterial activity against Mycobacterium intracellular	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID1647748	Cell cycle arrest in human HeLa cells assessed as accumulation at Sub G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 2.2%)
AID1491086	Inhibition of Staphylococcus aureus ATCC 6538p SortA expressed in Escherichia coli using Dabcyl-QALPETGEE-Edans as substrate after 1 hr by fluorescence spectrophotometric method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID355072	Antibacterial activity against Escherichia coli ATCC 25922 at 100 ug after 24 hrs by agar plate diffusion assay	1996	Journal of natural products, Nov, Volume: 59, Issue:11	Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica.
AID461363	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 7 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461346	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 after 72 hrs by LDH assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461598	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 100 mg/kg, perorally administered 1 day after infection measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647705	Antiproliferative activity against human C33A cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo assay
AID340548	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300	2008	Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14	2-N-Methyl modifications and SAR studies of manzamine A.
AID461589	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as survivability at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461373	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 14 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461631	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) assessed as weight loss at 300 mg/kg, perorally	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID377713	Toxicity against medaka eggs assessed as eggs failing to hatch after 11 days	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1647802	Inhibition of Human papillomavirus type16 derived E7 in human CaSki cells assessed as decrease in phosphorylation of Rb at 2 to 4 uM after 48 hrs by Western blot analysis
AID676761	Antiviral activity against HSV-1 infected in african green monkey Vero cells assessed as inhibition of GFP gene expression after 48 hrs by RT-PCR analysis	2012	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16	Antiviral activity and synthesis of quaternized promazine derivatives against HSV-1.
AID461874	Cell cycle arrest in human HeLa cells assessed as increase in S phase accumulation at 20 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID311308	Inhibition of recombinant CDK1	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
AID355069	Insecticidal activity against Spodoptera littoralis neonate larvae assessed as inhibition of larval growth drug administered with artificial diet after 6 days by chronic feeding experiment	1996	Journal of natural products, Nov, Volume: 59, Issue:11	Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica.
AID1647745	Cell cycle arrest in human SiHa cells assessed as accumulation at G2/M phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 14.7%)
AID328114	Antiinflammatory activity in Escherichia coli lipopolysaccharide-activated rat neonatal microglia assessed as inhibition of oxygen radical	2008	Journal of natural products, Mar, Volume: 71, Issue:3	Semisynthetic studies on the manzamine alkaloids.
AID461372	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 14 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461377	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 3.3 mg/kg, perorally administered 1 day after infection for 3 days measured after 21 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1158609	Inhibition of cholesterol ester accumulation in mouse macrophages at 20 uM	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Acantholactam and pre-neo-kauluamine, manzamine-related alkaloids from the Indonesian marine sponge Acanthostrongylophora ingens.
AID461376	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 1.1 mg/kg, perorally administered 1 day after infection for 3 days measured after 21 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647736	Cell cycle arrest in human C33A cells assessed as accumulation at Sub G1 phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 0.8%)
AID1647732	Cytotoxicity against human Keratinocytes assessed as reduction in cell viability 2 to 4 uM incubated up to 72 hrs by CellTiter-Glo assay
AID1647760	Cell cycle arrest in human CaSki cells assessed as accumulation at G2/M phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 29.5%)
AID1491087	Inhibition of Magnaporthe grisea Guy 11 ICL	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID461597	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 50 mg/kg, perorally administered as single dose measured after 5 days of inoculation	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID311310	Inhibition of recombinant MAPK	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease.
AID1647826	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human CaSki cells after 48 hrs by Western blot analysis
AID1647730	Inhibition of CK2alpha in human C33A cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID461620	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as survivability at 10 mg/kg, intraperitoneally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461387	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) at 5 mg/kg, po	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647810	Inhibition of SIX1 in human HeLa cells at 2 to 4 uM after 48 hrs by Western blot analysis
AID377707	Inhibition of bovine AChE	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID461366	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID377712	Cytotoxicity against human SH-SY5Y cells at 5 uM	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID377711	Inhibition of GSK3-beta in human SH-SY5Y cells assessed as inhibition of tau phosphorylation at Ser396 at 5 uM after 24 hrs by ELISA sandwich method	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID1647807	Cell cycle arrest in human C33A cells assessed as increase in p21 protein expression at 2 to 4 uM after 48 hr by Western lot analysis
AID1647774	Induction of apoptosis in human SiHa cells assessed as late apoptotic cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 2.3%)
AID377702	Antibacterial activity against Staphylococcus aureus	2006	Journal of natural products, Jul, Volume: 69, Issue:7	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
AID461608	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 14 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461617	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 200 mg/kg, perorally administered 1 day after infection measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647830	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of SIX1 in human CaSki cells after 48 hrs by Western blot analysis
AID461355	Antineuroinflammatory activity in LPS-stimulated rat neonatal microglia assessed as inhibition of PMA-induced superoxide anion production preincubated 15 mins prior to PMA challenge measured after 70 mins	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1316811	Cytotoxicity against human NCI-H1373 cells assessed as decrease in cell viability after 48 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20	PUMA-dependent apoptosis in NSCLC cancer cells by a dimeric β-carboline.
AID461594	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 50 mg/kg, perorally administered 1 day after infection measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647749	Cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 69.4%)
AID333080	Antibacterial activity against Cryptococcus neoformans	2004	Journal of natural products, Aug, Volume: 67, Issue:8	Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.
AID340602	Antimalarial activity as reduced parasitaemia at day 14 in Plasmodium berghei NK65 infected mice (Mus musculus) at 10 mg/kg peroral dose three times daily for 2 days post infection	2008	Journal of natural products, Jul, Volume: 71, Issue:7	Kinetic studies and bioactivity of potential manzamine prodrugs.
AID355988	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv	2003	Journal of natural products, Jun, Volume: 66, Issue:6	New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge.
AID1647766	Induction of apoptosis in human C33A cells assessed as viable cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 82.8%)
AID754963	Cytotoxicity against human MDM assessed as inhibition of acetylated LDL-induced [3H]-triglyceride synthesis at 50 uM after 24 hrs by radioscanner analysis in presence of [3H]-oleate-conjugated BSA	2013	Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13	Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
AID461630	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) assessed as weight loss at 200 mg/kg, perorally	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1491081	Antibacterial activity against Proteus hauseri NBRC 3851 after 24 hrs by serial two fold dilution method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID1647747	Cell cycle arrest in human SiHa cells assessed as accumulation at G2/M phase at 4 uM after 72 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 18%)
AID461382	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 28 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461385	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) at 3.3 mg/kg, po	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461354	Antimycobacterial activity against Mycobacterium intracellular ATCC 23068	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID1647772	Induction of apoptosis in human SiHa cells assessed as viable cells at 4 uM after 48 hrs by Annexin V-FITC/PI double staining based flow cytometric analysis (Rvb = 93.7%)
AID461362	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 10 mg/kg, perorally administered 1 day after infection for 3 days measured after 5 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461604	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 100 mg/kg, perorally administered 1 day after infection measured after 10 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID397143	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	1993	Journal of natural products, Jun, Volume: 56, Issue:6	Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID1647759	Cell cycle arrest in human CaSki cells assessed as accumulation at G0/G1 phase at 4 uM after 48 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 54.1%)
AID397142	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	1993	Journal of natural products, Jun, Volume: 56, Issue:6	Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity.
AID1491082	Antibacterial activity against Escherichia coli ATCC 35270 after 24 hrs by serial two fold dilution method	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	Manzamine Alkaloids from an Acanthostrongylophora sp. Sponge.
AID461375	Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 5 mg/kg, perorally administered 1 day after infection for 3 days measured after 14 days post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID452170	Antibacterial activity against Mycobacterium intracellular by alamar blue assay	2009	Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22	Structure-activity relationship studies of manzamine A: amidation of positions 6 and 8 of the beta-carboline moiety.
AID355990	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2	2003	Journal of natural products, Jun, Volume: 66, Issue:6	New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge.
AID401053	Antibacterial activity against Sarcina lutea	1998	Journal of natural products, May, Volume: 61, Issue:5	Three new manzamine congeners from amphimedon sponge
AID1466360	Antimalarial activity against Plasmodium falciparum D6	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.
AID461627	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) assessed as weight loss until day 5 of post infection	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID461629	Toxicity in Plasmodium berghei NK65 infected Swiss Webster mice (Mus musculus) assessed as behavioral change at 100 mg/kg, perorally	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections.
AID12671	Half-life at 10 mg/kg in rat upon intravenous administration	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID10897	Tmax in rats	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID207536	Minimal inhibitory concentration against methicillin-resistant Staphylococcus aureus; Range is 0.5-6.25 ug/mL	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID54865	Inhibitory concentration against Cryptococcus neoformans	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID206708	Inhibitory concentration against methicillin-resistant Staphylococcus aureus	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID206705	Inhibitory concentration against Staphylococcus aureus	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID81266	Effective concentration against HIV-1	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID546578	Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
AID11435	Cmax in rats	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID12131	AUC0-96 after administration at 50 mg/kg	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID144142	Minimal inhibitory concentration against Mycobacterium intracellular; Range is 0.5-6.25 ug/mL	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID144027	Inhibitory concentration against Mycobacterium intracellular	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID11081	Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID546577	Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
AID19208	Partition coefficient (logP)	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID546576	Inhibition of recombinant GSK3-beta at 10 uM by Z'-LYTE kinase assay kit method	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
AID13338	Oral bioavailability in rat	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID207535	Minimal inhibitory concentration against Staphylococcus aureus; Range is 0.5-6.25 ug/mL	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
AID13455	Plasma clearance at 10 mg/kg in rat upon intravenous administration	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	5 (7.04)	18.2507
2000's	30 (42.25)	29.6817
2010's	26 (36.62)	24.3611
2020's	10 (14.08)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	7 (9.86%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	64 (90.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.01	1	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
pd 173074 [no description available]	2.07	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
3-nitropropionic acid 3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE. 3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.	2.15	1	C-nitro compound	antimycobacterial drug; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; mycotoxin; neurotoxin
arecoline Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.. arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.	2.01	1	enoate ester; methyl ester; pyridine alkaloid; tetrahydropyridine	metabolite; muscarinic agonist
caffeine [no description available]	2.05	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	3.64	9	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	3.42	7	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.31	1	carbohydrazide	antitubercular agent; drug allergen
nocodazole [no description available]	2.02	1	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	2.94	4	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
gliotoxin Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent.. gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi.	3.31	1	dipeptide; organic disulfide; organic heterotetracyclic compound; pyrazinoindole	antifungal agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; immunosuppressive agent; mycotoxin; proteasome inhibitor
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	2.15	1	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
4-butyrolactone 4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.	2.31	1	butan-4-olide	metabolite; neurotoxin
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	4.09	15	pyrrole; secondary amine
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	3.41	1	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.04	1	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrrolnitrin Pyrrolnitrin: 3-Chloro-4-(3-chloro-2-nitrophenyl)pyrrole. Antifungal antibiotic isolated from Pseudomonas pyrrocinia. It is effective mainly against Trichophyton, Microsporium, Epidermophyton, and Penicillium.. pyrrolnitrin : A member of the class of pyrroles carrying chloro and 3-chloro-2-nitrophenyl substituents at positions 3 and 4 respectively.	2.15	1	alkaloid; C-nitro compound; monochlorobenzenes; pyrroles	antifungal drug; bacterial metabolite
tiletamine hydrochloride Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.	2	1
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	3.84	3	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ribavirin Rebetron: Rebetron is tradename	2.05	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
norharman norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.	2.44	2	beta-carbolines; mancude organic heterotricyclic parent	fungal metabolite; marine metabolite
meridine meridine: polycyclic alkaloid derived from the marine sponge Corticium sp; structure given in first source	1.98	1
puupehenone [no description available]	3.53	2
cryptolepine cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta. cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group.	3.25	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound	anti-inflammatory agent; antimalarial; antineoplastic agent; cysteine protease inhibitor; plant metabolite
tetrahydroharmane [no description available]	3.41	1
24-methylenecholesterol 24-methylenecholesterol: RN given refers to (3beta)-isomer; structure. 24-methylenecholesterol : A 3beta-sterol having the structure of cholesterol with a methylene group at C-24.	3.31	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol	mouse metabolite
canthin-6-one canthin-6-one: from Zanthoxylum usambarense; structure in first source. canthin-6-one : An indole alkaloid that is 6H-indolo[3,2,1-de][1,5]naphthyridine substituted by an oxo group at position 6.	3.25	1	enone; indole alkaloid; organic heterotetracyclic compound	antimycobacterial drug; metabolite
cryptolepine monohydrochloride [no description available]	3.25	1
avasimibe [no description available]	2.08	1	monoterpenoid
f 1394 F 1394: an acyl-CoA:cholesterol acyltransferase (ACAT) inibitor; structure given in first source	2.08	1
brevianamide f brevianamide F: isolated from the endophyte from Aspergillus fumigatus associated with Melia azedarach L that could be used to develop a natural eco-friendly herbicide.structure in first source. brevianamide F : A pyrrolopyrazine that is hexahydropyrrolo[1,2-a]pyrazine-1,4-dione bearing an indol-3-ylmethyl substituent at position 3 (the 3S,8aS-diastereomer, obtained by formal cyclocondensation of L-tryptophan and L-proline).	3.31	1	dipeptide; indoles; pyrrolopyrazine	metabolite
aricine heterophylline: from the leaves of Heterophyllaea pustulata; structure in first source	3.41	1	methyl ester; yohimban alkaloid
uleine uleine: from the bark of Plumeria lancifolia; structure in first source	3.25	1
22-epi-hippuristanol [no description available]	1.98	1
neocryptolepine neocryptolepine: isolated from the roots of the African plant Cryptolepis sanguinolenta; structure in first source	3.25	1
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	2.15	1	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
strychnine Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.	3.51	1	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
brucine brucine: was heading 1991-94 (see under STRYCHNINE 1975-90); DIMETHOXYSTRYCHNINE was see BRUCINE 1975-94; use STRYCHNINE to search BRUCINE 1975-94; very toxic alkaloid from Nux vomica similar to strychnine; used as reagent in analytical chemistry; was MH 1991-94	3.51	1	monoterpenoid indole alkaloid; organic heteroheptacyclic compound
latrunculin a latrunculin A: 16-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin B; structure given in first source. latrunculin A : A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes.	1.98	1	cyclic hemiketal; macrolide; oxabicycloalkane; thiazolidinone	actin polymerisation inhibitor; metabolite; toxin
4-hydroxyphenylmethylene hydantoin 4-hydroxyphenylmethylene hydantoin: isoalted from the Red Sea sponge Hemimycale arabica; structure in first source	2.05	1
lithium Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.	2	1	alkali metal atom
quinine [no description available]	2.05	1	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.07	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
pactimibe [no description available]	2.08	1
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.	2.07	1	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
epinephrine ircinal A: from an Indonesian Acanthostrongylophora sponge with activity against infectious, tropical parasitic, and Alzheimer's diseases; structure in first source	5.06	7
8-hydroxymanzamine a 8-hydroxymanzamine A: active against HIV-II; isolated from the sponge Pachypellina; structure in first source. 8-hydroxymanzamine A : An alkaloid that is manzamine A with a hydroxy substituent at position 8. Isolated from Pachypellina and Acanthostrongylophora, it exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26).	9.63	4	alkaloid; beta-carbolines; isoquinolines	anti-HSV-2 agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; metabolite
quercetin [no description available]	3.51	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	3.53	8	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	2.02	1	thromboxanes B	human metabolite; mouse metabolite
caulerpin caulerpin: pigment from green algae, Caulerpa lamourouxii; structure	3.31	1
su 11248 [no description available]	2.07	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
sclerotiorin sclerotiorin: isolated from monoverticillate Penicillia; RN given for (R-(R,S-(E,E)))-isomer; structure in first source	3.31	1	azaphilone
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.08	1	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
laq824 LAQ824: Histone deacetylase inhibitor	3.25	1
manzamine f manzamine F: manzamine alkaloid with potent activity against infectious diseases; structure in first source	2.98	4
pseudopteroxazole pseudopteroxazole: structure in first source	3.31	1	tetralins	metabolite
jasplakinolide jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R,4E,6S,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.	2.04	1	cyclodepsipeptide; phenols	actin polymerisation inducer; animal metabolite; antifungal agent; antineoplastic agent; apoptosis inducer; marine metabolite; neuroprotective agent
discorhabdin p discorhabdin P: sulfur-containing pyrroloiminoquinone alkaloid (or benzothiazepine); an enzyme inhibitor from a deep-water caribbean sponge of the Genus batzella; structure in first source	1.98	1
manzamine b manzamine B: from an Indonesian Acanthostrongylophora sponge with activity against infectious, tropical parasitic, and Alzheimer's diseases; structure in first source	4.75	5
madangamine a madangamine A: from sponge Xestospongia ingens; structure in first source	3.35	1
neoechinulin a neoechinulin A: from the marine-derived fungus Aspergillus sp.; structure in first source	2.04	1
demethyloxyaaptamine demethyloxyaaptamine: from Hymeniacidon sp.; structure in first source	1.98	1
bibw 2992 [no description available]	2.07	1	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
eudistomin u eudistomin U: an alkaloid from the Carribean ascidian Lissoclinum fragile; structure given in first source	3.41	1
halicyclamine a halicyclamine A: structure in first source	3.31	1
pf-562,271 [no description available]	3.25	1	indoles
serotobenine serotobenine: isolated from Ouratea turnarea	3.51	1
1,4-dihydroxy-2-methoxy-7-methylanthraquinone [no description available]	3.31	1
bengazole a bengazole A: isolated from Jaspis marine sponges; structure in first source	2.04	1
(1S,3aR,4S,6S,6aS,9aS,9bS)-9a-isocyano-6-(2-isocyano-2-methylpropyl)-1,4-dimethyl-7-methylidene-2,3,3a,4,5,6,6a,8,9,9b-decahydro-1H-phenalene [no description available]	1.98	1	diterpenoid	metabolite
proximicin b proximicin B: antineoplastic agent isolated from Verrucosispora; structure in first source	3.31	1
piperidines Piperidines: A family of hexahydropyridines.	3.35	1
sodium artesunate [no description available]	2.05	1
manzamine e manzamine E: from an Indonesian Acanthostrongylophora sponge with activity against infectious, tropical parasitic, and Alzheimer's diseases; structure in first source	4.74	9
neo-kauluamine neo-kauluamine: manzamine alkaloid with potent activity against infectious diseases; structure in first source	2.96	4
sch 419560 Sch 419560: isolated from Pseudomonas fluorescens; structure in first source	3.31	1
palinurin palinurin: an NSAID with antibacterial activity; isolated from Ircinia species; structure in firs t source	2.07	1
palau'amine palau'amine: structure in first source	2.31	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.07	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	5.05	7	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	3.51	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
indolmycin indolmycin: produced by a strain of Streptomyces griseus; RN given refers to cpd without isomeric designation; structure. indolmycin : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted at the 2 and 5-pro-S positions by methylamino and [(1R)-1-(1H-indol-3-yl)ethyl] groups, respectively.	3.25	1	1,3-oxazoles; indoles; secondary amino compound	antibacterial agent; antimicrobial agent; bacterial metabolite; EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor
4-deoxybostrycin 4-deoxybostrycin: crystalline red pigment from culture filtrate of Alternaria eichhorniae with antibacterial & phytotoxic activity; structure given in first source	3.31	1
trigonoliimine a trigonoliimine A: from the leaves of Trigonostemon lii; structure in first source	3.25	1

Condition	Relationship Strength	Studies
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.39	2
AIDS-Related Opportunistic Infections Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.	2.02	1
Acute Confusional Senile Dementia [description not available]	2.44	2
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.44	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.04	1
Neurogenic Inflammation Inflammation caused by an injurious stimulus of peripheral neurons and resulting in release of neuropeptides which affect vascular permeability and help initiate proinflammatory and immune reactions at the site of injury.	2.05	1
Cerebellar Diseases Diseases that affect the structure or function of the cerebellum. Cardinal manifestations of cerebellar dysfunction include dysmetria, GAIT ATAXIA, and MUSCLE HYPOTONIA.	2.05	1
Atherogenesis [description not available]	2.08	1
Hyperlipemia [description not available]	2.08	1
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.08	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	7.08	1
Carcinoma, Non-Small Cell Lung [description not available]	2.13	1
Cancer of Lung [description not available]	2.13	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.13	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.13	1
Bacterial Disease [description not available]	3.06	1
Abdominal Migraine [description not available]	3.06	1
Fungal Diseases [description not available]	3.06	1
Benign Neoplasms [description not available]	3.06	1
Viral Diseases [description not available]	3.06	1
Bacterial Infections Infections by bacteria, general or unspecified.	3.06	1
Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)	3.06	1
Mycoses Diseases caused by FUNGI.	3.06	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.06	1
Virus Diseases A general term for diseases caused by viruses.	3.06	1
Koch's Disease [description not available]	3.12	1
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	3.12	1
Infections, Plasmodium [description not available]	4.35	4
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	9.35	4
Cancer of Cervix [description not available]	2.31	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.31	1
Breast Cancer [description not available]	2.6	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.6	1
Fibroid [description not available]	2.6	1
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	7.6	1
Colorectal Cancer [description not available]	7.17	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.17	1
Cancer of Pancreas [description not available]	2.48	2
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.48	2
Metastase [description not available]	2.06	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.06	1
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	2	1

manzamine a

Description

Cross-References

Synonyms (16)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Bioavailability

Roles (6)

Drug Classes (3)

Protein Targets (9)

Inhibition Measurements

Biological Processes (214)

Molecular Functions (53)

Ceullar Components (48)

Bioassays (393)

Research

Studies (71)

Market Indicators

Research Demand Index: 27.99

Study Types

manzamine a

Description

Cross-References

Synonyms (16)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Bioavailability

Roles (6)

Drug Classes (3)

Protein Targets (9)

Inhibition Measurements

Biological Processes (214)

Molecular Functions (53)

Ceullar Components (48)

Bioassays (393)

Research

Studies (71)

Market Indicators

Research Demand Index: 27.99

Study Types

Related Drugs (85)

Related Conditions (42)